Precision Molecular Pathology of Lung Cancer

[1]  F. Hirsch,et al.  PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  Alan Sharpe,et al.  Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non–Small Cell Lung Cancer , 2017, Clinical Cancer Research.

[3]  Marshall W. Anderson,et al.  Familial Lung Cancer: A Brief History from the Earliest Work to the Most Recent Studies , 2017, Genes.

[4]  Bo Ram Kim,et al.  SOX2 and PI3K Cooperate to Induce and Stabilize a Squamous-Committed Stem Cell Injury State during Lung Squamous Cell Carcinoma Pathogenesis , 2016, PLoS biology.

[5]  Sarah H. Johnson,et al.  Custom Gene Capture and Next‐Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  S. Dacic,et al.  ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma , 2016, Oncotarget.

[7]  E. Felip,et al.  P2.35: Nivolumab vs Docetaxel in Advanced NSCLC: CheckMate 017/057 2-Y Update and Exploratory Cytokine Profile Analysis: Track: Immunotherapy. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  M. Capone,et al.  Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015 , 2016, Journal of Translational Medicine.

[9]  M. Tiemann,et al.  [Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study]. , 2016, Der Pathologe.

[10]  L. Chin,et al.  Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. , 2016, Cancer discovery.

[11]  M. Ladanyi,et al.  Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. , 2016, The oncologist.

[12]  S. Digumarthy,et al.  EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis , 2016, Clinical Cancer Research.

[13]  P. Hegde,et al.  The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition , 2016, Clinical Cancer Research.

[14]  M. Kris,et al.  HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  R. Govindan,et al.  Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Socinski,et al.  Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. , 2016, The Lancet. Oncology.

[17]  P. Jänne,et al.  Clinical Implications of Variant ALK FISH Rearrangement Patterns , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[19]  Y. Ohe,et al.  Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study) , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Gary K. Schwartz,et al.  Alternative transcription initiation leads to expression of a novel ALK isoform in cancer , 2015, Nature.

[21]  H. Asamura,et al.  Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer. , 2015, Clinical lung cancer.

[22]  Yixin Zeng,et al.  BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  M. Mino‐Kenudson,et al.  Primary Pulmonary NUT Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterizations , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  H. Sugimura,et al.  NSD3-NUT-expressing midline carcinoma of the lung: first characterization of primary cancer tissue. , 2015, Pathology, research and practice.

[25]  D. Planchard,et al.  Lung cancer in never-smokers , 2015, European Respiratory Journal.

[26]  A. Bossler,et al.  Germline mutations predisposing to non-small cell lung cancer , 2015, Familial Cancer.

[27]  F. Hirsch,et al.  Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. , 2015, The oncologist.

[28]  J. Engelman,et al.  Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib , 2015, Clinical Cancer Research.

[29]  Shingo Matsumoto,et al.  Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. , 2015, Translational lung cancer research.

[30]  B. Blencowe,et al.  Canadian Anaplastic Lymphoma Kinase Study: A Model for Multicenter Standardization and Optimization of ALK Testing in Lung Cancer , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[31]  C. Bacchi,et al.  Expression of P16 in NUT Carcinomas With No Association With Human Papillomavirus (HPV) , 2014, Applied immunohistochemistry & molecular morphology : AIMM.

[32]  T. Kohno,et al.  RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis , 2014, British Journal of Cancer.

[33]  M. Socinski,et al.  RET Rearrangements in Lung Adenocarcinoma and Radiation , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[34]  Jian-Hua Fu,et al.  Lack of epidermal growth factor receptor gene mutations in exons 19 and 21 in primary lymphoepithelioma‐like carcinoma of the lung , 2014, Thoracic cancer.

[35]  L. Garraway,et al.  Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer , 2013, Nature Medicine.

[36]  Abel N. Kho,et al.  Practical challenges in integrating genomic data into the electronic health record , 2013, Genetics in Medicine.

[37]  Iftikhar J. Kullo,et al.  Ethical, legal, and social implications of incorporating genomic information into electronic health records , 2013, Genetics in Medicine.

[38]  Andrew G. Ury,et al.  Storing and interpreting genomic information in widely deployed electronic health record systems , 2013, Genetics in Medicine.

[39]  Robert Brian Jenkins,et al.  Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[40]  Y. Ohe,et al.  CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. , 2013, The Lancet. Oncology.

[41]  S. Dacic,et al.  Sex-determining region Y-box 2 amplification in preneoplastic squamous lesions of the lung. , 2013, Human pathology.

[42]  W. Franklin,et al.  Diagnostic assays for identification of anaplastic lymphoma kinase‐positive non–small cell lung cancer , 2013, Cancer.

[43]  Teresa Kay,et al.  Nonoptical Massive Parallel DNA Sequencing of BRCA1 and BRCA2 Genes in a Diagnostic Setting , 2013, Human mutation.

[44]  L. Chirieac,et al.  Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK-Rearranged Lung Adenocarcinomas , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[45]  H. Ji,et al.  RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Jeffrey W. Clark,et al.  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. , 2012, The Lancet. Oncology.

[47]  M. Varella‐Garcia,et al.  Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization–positive nonsmall cell lung cancer , 2012, Cancer.

[48]  P. Stephens,et al.  Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[49]  H. Sasaki,et al.  RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer , 2012, Cancer medicine.

[50]  T. Mok,et al.  Smoking history as a predictive factor of treatment response in advanced non-small-cell lung cancer: a systematic review. , 2012, Clinical lung cancer.

[51]  T. Gu,et al.  Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non–Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion , 2012, Clinical Cancer Research.

[52]  Sébastien Couraud,et al.  Lung cancer in never smokers--a review. , 2012, European journal of cancer.

[53]  Mio Tanaka,et al.  NUT Midline Carcinoma: Report of 2 Cases Suggestive of Pulmonary Origin , 2012, The American journal of surgical pathology.

[54]  Yuki Togashi,et al.  RET, ROS1 and ALK fusions in lung cancer , 2012, Nature Medicine.

[55]  Yasushi Totoki,et al.  KIF5B-RET fusions in lung adenocarcinoma , 2012, Nature Medicine.

[56]  T. Nakajima,et al.  KLC1-ALK: A Novel Fusion in Lung Cancer Identified Using a Formalin-Fixed Paraffin-Embedded Tissue Only , 2012, PloS one.

[57]  A. Iafrate,et al.  Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers , 2012, Science Translational Medicine.

[58]  E. Brambilla,et al.  Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice: A French Study , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[59]  Tatiana G. Kutateladze,et al.  Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[60]  R. Hopkins,et al.  How the genetics of lung cancer may overlap with COPD , 2011, Respirology.

[61]  Bernard P. Puc,et al.  An integrated semiconductor device enabling non-optical genome sequencing , 2011, Nature.

[62]  Joshua S. Paul,et al.  Genotype and SNP calling from next-generation sequencing data , 2011, Nature Reviews Genetics.

[63]  T. Sethi,et al.  Advances in the prevention and treatment of lung cancer. , 2011, The journal of the Royal College of Physicians of Edinburgh.

[64]  Ian M. Adcock,et al.  Chronic Obstructive Pulmonary Disease and Lung Cancer: New Molecular Insights , 2011, Respiration.

[65]  Yih-Leong Chang,et al.  Unique p53 and epidermal growth factor receptor gene mutation status in 46 pulmonary lymphoepithelioma‐like carcinomas , 2011, Cancer science.

[66]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[67]  Young Lim Choi,et al.  EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. , 2010, The New England journal of medicine.

[68]  A. Gazdar,et al.  A risky business--identifying susceptibility loci for lung cancer. , 2010, Journal of the National Cancer Institute.

[69]  T. Rabbitts,et al.  Progressive 3q amplification consistently targets SOX2 in preinvasive squamous lung cancer. , 2010, American journal of respiratory and critical care medicine.

[70]  D. Baird.  Variation at the TERT locus and predisposition for cancer , 2010, Expert Reviews in Molecular Medicine.

[71]  A. Regev,et al.  SOX2 Is an Amplified Lineage Survival Oncogene in Lung and Esophageal Squamous Cell Carcinomas , 2009, Nature Genetics.

[72]  Erika Avila-Tang,et al.  Lung Cancer in Never Smokers: Clinical Epidemiology and Environmental Risk Factors , 2009, Clinical Cancer Research.

[73]  C. Rudin,et al.  Lung Cancer in Never Smokers: A Call to Action , 2009, Clinical Cancer Research.

[74]  William Pao,et al.  Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications , 2009, Clinical Cancer Research.

[75]  R. Schwartz,et al.  Multiple roles for Sox2 in the developing and adult mouse trachea , 2009, Development.

[76]  Y. Ishikawa,et al.  KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer , 2009, Clinical Cancer Research.

[77]  A. Burny,et al.  Evolution of microRNA expression during human bronchial squamous carcinogenesis , 2008, European Respiratory Journal.

[78]  W. Foulkes,et al.  Inherited susceptibility to common cancers. , 2008, The New England journal of medicine.

[79]  A. Burny,et al.  The role of NPM, p14arf and MDM2 in precursors of bronchial squamous cell carcinoma , 2008, European Respiratory Journal.

[80]  T. Eisen,et al.  Identification of low penetrance alleles for lung cancer: the GEnetic Lung CAncer Predisposition Study (GELCAPS). , 2008, BMC cancer.

[81]  Yuki Togashi,et al.  Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. , 2008, Cancer research.

[82]  Antony V. Cox,et al.  Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing , 2008, Nature Genetics.

[83]  G. Ceresoli,et al.  Molecular Alterations in Spontaneous Sputum of Cancer-Free Heavy Smokers: Results from a Large Screening Program , 2008, Clinical Cancer Research.

[84]  S. Lam,et al.  Chromosomal aneusomy in bronchial high-grade lesions is associated with invasive lung cancer. , 2008, American journal of respiratory and critical care medicine.

[85]  Y. Nakanishi,et al.  Lung cancer susceptibility: are we on our way to identifying a high-risk group? , 2007, Future oncology.

[86]  A. Gazdar,et al.  Lung cancer in never smokers — a different disease , 2007, Nature Reviews Cancer.

[87]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[88]  M. Spitz,et al.  Never smokers and lung cancer risk: A case‐control study of epidemiological factors , 2006, International journal of cancer.

[89]  Marshall W. Anderson,et al.  Increased staining for phospho-Akt, p65/RELA and cIAP-2 in pre-neoplastic human bronchial biopsies , 2005, BMC Cancer.

[90]  Yongtang Jin,et al.  Increased risk of cancer among relatives of patients with lung cancer in China , 2005, BMC Cancer.

[91]  T. Eisen,et al.  Systematic review of the relationship between family history and lung cancer risk , 2005, British Journal of Cancer.

[92]  Y. Miller,et al.  Lung cancer: genetics of risk and advances in chemoprevention , 2005, Current opinion in pulmonary medicine.

[93]  X. He,et al.  Familial aggregation of lung cancer in a high incidence area in China , 2005, British Journal of Cancer.

[94]  K. Hemminki,et al.  Familial multiple primary lung cancers: a population-based analysis from Sweden. , 2005, Lung cancer.

[95]  K. Hemminki,et al.  FAMILIAL RISK FOR LUNG CANCER BY HISTOLOGY AND AGE OF ONSET: EVIDENCE FOR RECESSIVE INHERITANCE , 2005, Experimental lung research.

[96]  D. Gudbjartsson,et al.  Familial risk of lung carcinoma in the Icelandic population. , 2004, JAMA.

[97]  P. Massion,et al.  Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. , 2004, American journal of respiratory and critical care medicine.

[98]  K. Hemminki,et al.  Inherited predisposition to early onset lung cancer according to histological type , 2004, International journal of cancer.

[99]  Marshall W. Anderson,et al.  A major lung cancer susceptibility locus maps to chromosome 6q23-25. , 2004, American journal of human genetics.

[100]  A. Schwartz.  Genetic predisposition to lung cancer. , 2004, Chest.

[101]  P. Brennan,et al.  Exon 5 Polymorphisms in the O6-Alkylguanine DNA Alkyltransferase Gene and Lung Cancer Risk in Non–Smokers Exposed to Second-Hand Smoke , 2004, Cancer Epidemiology Biomarkers & Prevention.

[102]  M. Spitz,et al.  Risk for smoking-related cancer among relatives of lung cancer patients. , 2003, Cancer research.

[103]  M. Spitz,et al.  Genetic Susceptibility for Lung Cancer: Interactions with Gender and Smoking History and Impact on Early Detection Policies , 2003, Human Heredity.

[104]  A. Rooney.  Family history reveals lung-cancer risk. , 2003, The Lancet. Oncology.

[105]  Y. Miller,et al.  Genetic susceptibility to lung cancer. , 2003, Seminars in respiratory and critical care medicine.

[106]  C. Ulrich,et al.  Polymorphisms in DNA repair genes and associations with cancer risk. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[107]  L. Thiberville,et al.  Aberrant methylation of the CDKN2a/p16INK4a gene promoter region in preinvasive bronchial lesions: A prospective study in high‐risk patients without invasive cancer. , 2002, International journal of cancer.

[108]  P. Boffetta,et al.  Familial cancer aggregation and the risk of lung cancer. , 2002, Sao Paulo medical journal = Revista paulista de medicina.

[109]  K. Hemminki,et al.  Familial and second esophageal cancers: A nation‐wide epidemiologic study from Sweden , 2002, International journal of cancer.

[110]  P. Dayer,et al.  Metabolic genetic polymorphisms and susceptibility to lung cancer. , 2001, Lung cancer.

[111]  W. Ahrens,et al.  Aggregation of lung cancer in families: results from a population-based case-control study in Germany. , 2000, American journal of epidemiology.

[112]  A. Aggarwal,et al.  Familial aggregation of cancer in patients with bronchogenic carcinoma. , 2000, Indian journal of cancer.

[113]  E. Bowman,et al.  Environmental tobacco smoke, genetic susceptibility, and risk of lung cancer in never-smoking women. , 1999, Journal of the National Cancer Institute.

[114]  S. Mayne,et al.  Familial cancer history and lung cancer risk in United States nonsmoking men and women. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[115]  G. Swanson,et al.  Lung cancer risk in families of nonsmoking probands: Heterogeneity by age at diagnosis , 1999, Genetic epidemiology.

[116]  K. Hemminki,et al.  Familial cancers in a nationwide family cancer database: age distribution and prevalence. , 1999, European journal of cancer.

[117]  A. Schwartz,et al.  Analysis of age of onset data from case-control family studies. , 1998, Biometrics.

[118]  E. Brambilla,et al.  p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bcl2, Bax, and Waf1) in precursor bronchial lesions of lung cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[119]  H. Wichmann,et al.  Risk factors for lung cancer in young adults. , 1998, American journal of epidemiology.

[120]  Kenji Suzuki,et al.  Microsatellite instability in female non-small-cell lung cancer patients with familial clustering of malignancy. , 1998, British Journal of Cancer.

[121]  Y. Miller,et al.  Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. , 1997, The Journal of clinical investigation.

[122]  F P Perera,et al.  Contribution of genetic and nutritional factors to DNA damage in heavy smokers. , 1997, Carcinogenesis.

[123]  M Feychting,et al.  Cancer in twins: genetic and nongenetic familial risk factors. , 1997, Journal of the National Cancer Institute.

[124]  G. Swanson,et al.  Familial risk of lung cancer among nonsmokers and their relatives. , 1996, American journal of epidemiology.

[125]  M. Osada,et al.  Assessment of cancer susceptibility in humans by use of genetic polymorphisms in carcinogen metabolism. , 1995, Pharmacogenetics.

[126]  A. Gazdar,et al.  K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas. , 1994, Cancer research.

[127]  T. Sellers,et al.  Segregation analysis of smoking-associated malignancies: evidence for Mendelian inheritance. , 1994, American journal of medical genetics.

[128]  R. Hoover,et al.  Genetic component of lung cancer: cohort study of twins , 1994, The Lancet.

[129]  T. Sellers,et al.  Increased familial risk for non-lung cancer among relatives of lung cancer patients. , 1987, American journal of epidemiology.

[130]  R. Elston,et al.  Familial lung cancer--correcting an error in calculation. , 1986, Journal of the National Cancer Institute.

[131]  D. Harnden.  Familial susceptibility to cancer. , 1983, British medical journal.

[132]  S. Chuai,et al.  Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[133]  S. Lantuejoul,et al.  PL04a.04: Multicentric French Harmonization Study for PD-L1 IHC Testing in NSCLC , 2017 .

[134]  C. Marquette,et al.  Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[135]  J. Engelman,et al.  Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[136]  Shibing Deng,et al.  Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer. , 2013, The Journal of molecular diagnostics : JMD.

[137]  A. Tsao,et al.  ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers , 2012 .

[138]  Q. Stein,et al.  Genetic and familial factors influencing breast, colon, prostate and lung cancers. , 2010, South Dakota medicine : the journal of the South Dakota State Medical Association.

[139]  Jun Yokota,et al.  Genetic basis for susceptibility to lung cancer: Recent progress and future directions. , 2010, Advances in cancer research.

[140]  A. Schwartz,et al.  Familial lung cancer: genetic susceptibility and relationship to chronic obstructive pulmonary disease. , 2006, American journal of respiratory and critical care medicine.

[141]  S. Land,et al.  GSTM 1 , GSTT 1 and GSTP 1 polymorphisms , environmental tobacco smoke exposure and risk of lung cancer among never smokers : a population-based study , 2005 .

[142]  T. Shirakawa,et al.  Genetic Polymorphisms and Environmental Risk of Lung Cancer: A Review , 2004, Reviews on environmental health.

[143]  W. Gauderman,et al.  Evidence for age-specific genetic relative risks in lung cancer. , 2000, American journal of epidemiology.

[144]  H. Bartsch,et al.  Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[145]  G. Swanson,et al.  Increased cancer risk among relatives of nonsmoking lung cancer cases , 1999, Genetic epidemiology.

[146]  C I Amos,et al.  Is there a genetic basis for lung cancer susceptibility? , 1999, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[147]  A. Hirvonen.  Polymorphic NATs and cancer predisposition. , 1999, IARC scientific publications.

[148]  A. Fryer,et al.  Interactions between detoxifying enzyme polymorphisms and susceptibility to cancer. , 1999, IARC scientific publications.

[149]  M. Spitz,et al.  Genetic susceptibility to tobacco carcinogenesis. , 1999, Cancer investigation.

[150]  W. Au,et al.  Interactions between genetic predisposition and environmental toxicants for development of lung cancer , 1997, Environmental and molecular mutagenesis.

[151]  G. Swanson,et al.  Genetic analysis of families with nonsmoking lung cancer probands , 1997, Genetic epidemiology.

[152]  T. Dragani,et al.  Polygenic inheritance of predisposition to lung cancer. , 1996, Annali dell'Istituto superiore di sanita.

[153]  Landi Mt,et al.  Molecular epidemiology: a new perspective for the study of toxic exposures in man. A consideration of the influence of genetic susceptibility factors on risk in different lung cancer histologies. , 1994, La Medicina del lavoro.

[154]  H. McDuffie,et al.  Clustering of cancer in families of patients with primary lung cancer. , 1991, Journal of clinical epidemiology.

[155]  J. Higginson,et al.  Epidemiological review of lung cancer in man. , 1977, IARC scientific publications.